Zofran Has Now Been Linked To Major Birth Defects. Have GlaxoSmithKline & The FDA Responded?
Since its approval in 1991, the anti-nausea drug Zofran has undergone several major labeling revisions. For a pharmaceutical product, this isn’t uncommon. When a drug... Read More
How Big Pharma Controls Drug Research
In our last article, we covered the numerous methods pharmaceutical manufacturers employ to buy the support of health care professionals, doctors and teaching hospitals. Drug... Read More
Pay To Promote: The Pharmaceutical Industry’s Financial Relationships With Doctors
In our last article, we discussed a series of charges filed by the US Department of Justice against the international pharmaceutical giant GlaxoSmithKline. We focused... Read More
Paying Doctors To Promote Drugs “Off Label”: The US Government’s Case Against GlaxoSmithKline
In 2012, the US Department of Justice brought a series of charges, both civil and criminal, against the London-based pharmaceutical conglomerate GlaxoSmithKline. Those charges were... Read More
Can Doctors Legally Prescribe Zofran For Morning Sickness?
Zofran, an anti-nausea drug manufactured by GlaxoSmithKline, has become a commonly prescribed medicine for morning sickness. In fact, it’s active ingredient ondansetron, has been placed on the... Read More
Beyond Possible Birth Defects: Zofran’s Other Health Risks
Now that several major studies have found a marked association between Zofran’s active ingredient ondansetron and birth defects, the medication has seen a lot of media... Read More
